Molecular Partners Forms Scientific Advisory Board to Accelerate Development of Targeted Radiotherapeutics

Core Insights - Molecular Partners AG has established a Scientific Advisory Board (SAB) for its radiopharmaceuticals, chaired by Prof. Ken Herrmann, a leading expert in nuclear medicine [1][4]. Group 1: Scientific Advisory Board Formation - The SAB will guide the development of Molecular Partners' Radio-DARPin platform, focusing on transitioning from early clinical validation to strategic clinical development [3][5]. - Prof. Ken Herrmann expressed enthusiasm for the potential of Radio-DARPins to deliver targeted radiopharmaceuticals effectively [2][8]. Group 2: Radio-DARPin Technology - Molecular Partners' Radio-DARPin candidates, including MP0712 and MP0726, are designed to target specific tumor markers, with MP0712 aimed at DLL3 for small cell lung cancer and MP0726 targeting mesothelin in various cancers [8]. - The technology aims to balance the delivery of potent radioactive payloads to tumors while minimizing damage to healthy tissues [8]. Group 3: Expertise of SAB Members - The SAB includes experts such as James Cook, Jason Lewis, and Michael Morris, who bring extensive clinical and industry experience to support the company's strategic development [5][6]. - Ken Herrmann's leadership is expected to be crucial in shaping the company's direction as it moves towards pivotal development decisions [5].